Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosis.
Alarcan H, Bruno C, Emond P, Raoul C, Vourc'h P, Corcia P, Camu W, Veyrune JL, Garlanda C, Locati M, Juntas-Morales R, Saker S, Suehs C, Masseguin C, Kirby J, Shaw P, Malaspina A, De Vos J, Al-Chalabi A, Leigh PN, Tree T, Bensimon G, Blasco H.
Alarcan H, et al. Among authors: veyrune jl.
Ann N Y Acad Sci. 2024 Jun;1536(1):82-91. doi: 10.1111/nyas.15147. Epub 2024 May 21.
Ann N Y Acad Sci. 2024.
PMID: 38771698
Clinical Trial.